Quarterly report pursuant to Section 13 or 15(d)


3 Months Ended
Mar. 31, 2013
Equity [Abstract]  
  8. Equity


During the first quarter of 2013, Navidea completed a public offering of 1,542,389 shares of the Company's common stock at a price of $3.10 per share less underwriting discounts and commissions (the February 2013 Offering). The net proceeds to the Company were approximately $4.5 million after deducting expenses associated with the February 2013 Offering. The Company will use the net proceeds from the February 2013 Offering to fund the clinical development and launch of its current drug products, to fund other potential product pipeline opportunities, and for general corporate purposes. The February 2013 Offering was underwritten by Ladenburg Thalmann & Co. Inc. and was made pursuant to the Company's existing effective shelf registration statement on Form S-3.